Role of tyrosine kinase inhibitors in the management of high-grade gliomas

Expert Review of Anticancer Therapy

Volumn 11, Issue 11, 2011, Pages 1739-1748

  Ahluwalia, Manmeet S ^a   Patel, Mital ^a   Peereboom, David M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Brain tumors; Chemotherapy; High grade gliomas; Resistance; Tyrosine kinase; Tyrosine kinase inhibitors

Indexed keywords

BAFETINIB; BEVACIZUMAB; BOSUTINIB; CABOZANTINIB; CEDIRANIB; CRENOLANIB; DASATINIB; ERLOTINIB; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LENVATINIB; LOMUSTINE; NILOTINIB; PAZOPANIB; PILARALISIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB; VOXTALISIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

AKT SIGNALING; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; DIARRHEA; DRUG RESISTANCE; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RENAL CELL CARCINOMA; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VEGF SIGNALING; BRAIN TUMOR; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; NEOPLASM GRADING; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84858741339     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.166     Document Type: Review

References (94)

1. Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J. Oncol. 2010, 689018 (2010).
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6), 15-18 (2002).
3. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8(8), 610-622 (2007).
4. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010).
5. Batchelor T, Mulholland, P Neyns. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study. Neuro. Oncol. 12(Suppl. 4), iv69-iv78 (2010).
6. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
7. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. 359(4), 378-390 (2008).
8. Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. N. Pharmacol. Exp. Ther. 319(3), 1070-1080 (2006).
9. Yu CR, Friday BB, Lai JP et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. 5(9), 2378-2387 (2006).
10. Wen PY, Cloughesy T, Kuhn J et al. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). ASCO Meeting Abstracts 27(15 Suppl.), 2006 (2009).
11. Prados M, Gilbert M, Kuhn J et al. Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). ASCO Meeting Abstracts 27(15S), 2005 (2009).
12. Peereboom D, Ye X, Nabors B et al. NABTT 0502: Phase 2 trial of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Presented at: Society for Neuro-Oncology Meeting. Dallas, TX, USA, 15-17 November 2007.
13. Hainsworth JD, Ervin T, Friedman E et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15), 3663-3669 (2010).
14. Reardon DA, Vredenburgh JJ, Desjardins A et al. Effect of CYP3A-inducing antiepileptics on sorafenib exposure: results of a Phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J. Neurooncol. 101(1), 57-66 (2011).
15. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544), 1329-1338 (2006).
16. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
17. Zhu AX, Raymond E. Early development of sunitinib in hepatocellular carcinoma. Expert Rev. Anticancer Ther. 9(1), 143-150 (2009).
18. Neyns B, Sadones J, Chaskis C et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J. Neurooncol. 103(3), 491-501 (2011).
19. Reardon DA, Vredenburgh JJ, Coan A et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J. Neurooncol. DOI: 10.1007/s11060-011-0627-0 (2011) (Epub ahead of print).
20. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs 9(12), 1324-1335 (2008).
21. Iwamoto FM, Lamborn KR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 12(8), 855-861 (2010).
22. Kurzrock R, Camacho L, Hong D et al. A Phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies. EJC Suppl. 4(12), 405 (2006).
23. Salgia R, Hong D, Sherman SI et al. A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Mol. Cancer Ther. 6(12), 3385S-3385S (2007).
24. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225(1), 1-26 (2005).
25. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008).
26. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 7(4), 436-451 (2005).
27. Wen PY, Prados M, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). ASCO Meeting Abstracts 28(15 Suppl.), 2006 (2010).
28. Sathornsumetee S, Rich JN. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today 42(10), 657-670 (2006).
29. Rich JN, Sathornsumetee S, Keir ST et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res. 11(22), 8145-8157 (2005).
30. Yiin JJ, Hu B, Schornack PA et al. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol. Cancer Ther. 9(4), 929-941 (2010).
31. Damiano V, Melisi D, Bianco C et al. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin. Cancer Res. 11(15), 5639-5644 (2005).
32. Drappatz J, Norden AD, Wong ET et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 85-90 (2010).
33. Jost LM, Gschwind HP, Jalava T et al. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab. Dispos. 34(11), 1817-1828 (2006).
34. Saunders MP, Wilson R, Peeters M et al. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. Cancer Chemother. Pharmacol. 64(4), 665-672 (2009).
35. Scott EN, Meinhardt G, Jacques C, Laurent D, Thomas AL. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin. Invest. Drugs 16(3), 367-379 (2007).
36. Thomas AL, Morgan B, Horsfield MA et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. 23(18), 4162-4171 (2005).
37. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55(2), 426-432; discussion 432 (2004).
38. Conrad C, Friedman H, Reardon D et al. A Phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). ASCO Meeting Abstracts 22(14 Suppl.), 1512 (2004).
39. Reardon D, Friedman H, Yung WKA et al. A Phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). ASCO Meeting Abstracts 22(14 Suppl.), 1513 (2004).
40. Glen H, Mason S, Patel H, Macleod K, Brunton VG. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumour cell migration and invasion. BMC Cancer 11(1), 309 (2011).
41. Hermanson M, Funa K, Hartman M et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52(11), 3213-3219 (1992).
42. Brennan C, Momota H, Hambardzumyan D et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4(11), e7752 (2009).
43. Kilic T, Alberta JA, Zdunek PR et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60(18), 5143-5150 (2000).
44. Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. 12(16), 4899-4907 (2006).
45. Wen PY, Yung WK, Lamborn KR et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 11(6), 853-860 (2009).
46. Desjardins A, Quinn JA, Vredenburgh JJ et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J. Neuro-Oncol. 83(1), 53-60 (2007).
47. Reardon DA, Egorin MJ, Quinn JA et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme. J. Clin. Oncol. 23(36), 9359-9368 (2005).
48. Reardon DA, Dresemann G, Taillibert S et al. Multicentre Phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br. J. Cancer 101(12), 1995-2004 (2009).
49. Dresemann G, Weller M, Rosenthal MA et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 96(3), 393-402 (2010).
50. Dong Y, Jia L, Wang X et al. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. Int J. Oncol. 38(2), 555-569 (2011).
51. Stettner MR, Wang W, Nabors LB et al. Lyn kinase activity is the predominant cellular Src kinase activity in glioblastoma tumor cells. Cancer Res. 65(13), 5535-5543 (2005).
52. Du J, Bernasconi P, Clauser KR et al. Beadbased profiling of tyrosine kinase phosphorylation identifies Src as a potential target for glioblastoma therapy. Nat. Biotechnol. 27(1), 77-83 (2009).
53. Ahluwalia MS, Groot J, Liu WM, Gladson CL. Targeting Src in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett. 298(2), 139-149 (2010).
54. Lu-Emerson C, Norden AD, Drappatz J et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J. Neurooncol. 104(1), 287-291 (2010).
55. Puttini M, Coluccia AM, Boschelli F et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinibresistant Bcr-Abl+ neoplastic cells. Cancer Res. 66(23), 11314-11322 (2006).
56. Kimura S, Naito H, Segawa H et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 106(12), 3948-3954 (2005).
57. Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr. Opin. Investig. Drugs 11(12), 1450-1465 (2011).
58. Chakravarti A, Zhai G, Suzuki Y et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 22(10), 1926-1933 (2004).
59. Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23(4), 357-361 (2005).
60. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23(23), 5294-5304 (2005).
61. Prasad G, Sottero T, Yang X et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 13(4), 384-392 (2011).
62. Papadopoulos KP, Tabernero J, Patnaik A et al. A Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of a novel PI3K inhibitor, XL765, administered orally to patients with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) 26, 3510 (2008).
63. Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 71(1), 154-163 (2011).
64. Franceschi E, Cavallo G, Lonardi S et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre Phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br. J. Cancer 96(7), 1047-1051 (2007).
65. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133-142 (2004).
66. Raizer JJ, Abrey LE, Lassman AB et al. A Phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 12(1), 87-94 (2010).
67. Raizer JJ, Abrey LE, Lassman AB et al. A Phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 12(1), 95-103 (2010).
68. Vogelbaum MA, Peereboom D, Stevens G, Barnett GH, Brewer C. Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent blioblastoma multiforme: results of a Phase II study. Proceedings of: Ninth Meeting of the Society for Neuro-Oncology. Toronto, Canada, 18-21 November 2004 (Abstract TA-359).
69. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 12(12), 1300-1310 (2010).
70. Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 26(34), 5603-5609 (2008).
71. Peereboom DM, Shepard DR, Ahluwalia MS et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol. 98(1), 93-99 (2009).
72. Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27(4), 579-584 (2009).
73. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353(19), 2012-2024 (2005).
74. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848), 287-290 (2007).
75. Robins HI, Wen PY, Chang SM et al. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02). ASCO Meeting Abstracts 25(18 Suppl.), 2057 (2007).
76. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97(12), 880-887 (2005).
77. Thiessen B, Stewart C, Tsao M et al. A Phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother. Pharmacol. 65(2), 353-361 (2010).
78. Mir O, Blanchet B, Goldwasser F. Drug-induced effects on erlotinib metabolism. N. Engl. J. Med. 365(4), 379-380 (2011).
79. Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25(16), 2295-2305 (2007).
80. Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther. 336(1), 223-233 (2011).
81. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther. 334(1), 147-155 (2010).
82. Tang SC, Lagas JS, Lankheet NA et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int. J. Cancer DOI: 10.1002/ijc.26000 (2011) (Epub ahead of print).
83. Lagas JS, van Waterschoot RA, van Tilburg VA et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 15(7), 2344-2351 (2009).
84. ClinicalTrials.gov http://clinicaltrials.gov
85. ClinicalTrials.gov. Hospital; MG. A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma. National Library of Medicine. NLM Identifier: NCT00821080, Bethesda, MD, USA (2000) http://clinicaltrials.gov/ct2/show/NCT00821080
86. ClinicalTrials.gov. An Open-Label, Three-Cohort, Phase 2 Study of E7080 in Subjects With Recurrent Malignant Glioma. National Library of Medicine, Bethesda, MD, USA, NLM Identifier: NCT01137604 (2000) http://clinicaltrials.gov/show/NCT01137604
87. ClinicalTrials.gov. NIH; Warren Grant Magnuson Clinical Center. Tandutinib plus bevacizumab to treat recurrent brain tumors. National Library of Medicine, Bethesda, MD, USA, NLM Identifier: NCT00667394 (2000) www.cancer.gov/clinicaltrials/NCT00667394
88. ClinicalTrials.gov. Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer. National Library of Medicine, Bethesda, MD, USA, NLM Identifier NCT00959946 (2000) http://clinicaltrials.gov/ct2/show/NCT00959946
89. ClinicalTrials.gov. Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer. National Library of Medicine, Bethesda, MD, USA, NLM Identifier NCT00959946 (2000) http://clinicaltrials.gov/ct2/show/NCT00959946
90. ClinicalTrials.gov. National Cancer Institute; City of Hope Medical Center. BAFETINIB-P1-GBM-01: A Pilot Study Using Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Bafetinib in Patients With Recurrent Brain Tumors. National Library of Medicine, Bethesda, MD, USA, NLM Identifier NCT01234740 (2000) http://clinicaltrials.gov/ct2/show/NCT01234740
91. ClinicalTrials.gov. University of California SD. A Phase II Study of PDGFR Kinase Inhibitor in Biomarker-Enriched Recurrent Malignant Gliomas. National Library of Medicine, Bethesda, MD, USA, NLM Identifier NCT01140568 (2000) http://clinicaltrials.gov/show/NCT01140568
92. ClinicalTrials.gov. Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection. Bethesda, MD, USA; National Library of Medicine, USA (2000) http://clinicaltrials.gov/ct2/show/NCT01240460?term=xl765&rank=1
93. ClinicalTrials.gov. Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma. Bethesda, MD, USA; National Library of Medicine, USA (2000) http://clinicaltrials.gov/ct2/show/NCT01339052?term=bkm120&rank=6
94. ClinicalTrials.gov. Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme. Bethesda, MD, USA; National Library of Medicine, USA (2000) http://clinicaltrials.gov/ct2/show/NCT01349660?term=bkm120&rank=5